首页> 外文期刊>ACS Omega >Characterization of Protein Z-Dependent Protease Inhibitor/Antithrombin Chimeras Provides Insight into the Serpin Specificity of Coagulation Proteases
【24h】

Characterization of Protein Z-Dependent Protease Inhibitor/Antithrombin Chimeras Provides Insight into the Serpin Specificity of Coagulation Proteases

机译:蛋白质Z依赖的蛋白酶抑制剂/抗凝血酶嵌合体的表征提供了凝结蛋白酶的丝氨酸蛋白酶抑制剂特异性的见解。

获取原文
获取外文期刊封面目录资料

摘要

Protein Z (PZ)-dependent protease inhibitor (ZPI) and antithrombin (AT) are two physiological serpin inhibitors involved in the regulation of proteolytic activities of the blood coagulation cascade. ZPI has restricted protease specificity capable of inhibiting factors Xa (FXa) and XIa (FXIa) but exhibiting no reactivity with other coagulation proteases. Unlike ZPI, AT is a general inhibitor of all coagulation proteases and the only physiological inhibitor of factor IXa (FIXa). To understand the molecular determinants of protease specificity of the two serpins, we engineered two ZPI mutants in which the P12-P3′ residues of the reactive center loop of ZPI were replaced with either P12-P3′ or P12-P7′ residues of AT (ZPI–AT~(P12-P3′) and ZPI–AT~(P12-P7′)). The reactivity of chimeras with FXa was improved ~4–25-fold in the absence of PZ. Both chimeras inhibited FIXa with rate constants that were ~2 orders of magnitude higher than the rate of the AT inhibition of the protease. PZ improved the reactivity of chimeras with FIXa by another 2 orders of magnitude, rendering the chimeras potent inhibitors of FIXa so that the PZ-mediated inhibitory activity of the ZPI–AT chimeras toward FIXa was ~20-fold higher than that of the fondaparinux-catalyzed inhibition of FIXa by AT. Further studies revealed that the substitution of P1-Tyr of ZPI with an Arg is sufficient to convert the serpin to an effective inhibitor of FIXa. The potential therapeutic utility of the serpin chimeras as specific inhibitors of FIXa was diminished by findings that the chimeras function as effective substrates for other coagulation proteases.
机译:依赖Z蛋白(PZ)的蛋白酶抑制剂(ZPI)和抗凝血酶(AT)是参与调节血凝级联蛋白水解活性的两种生理丝氨酸蛋白酶抑制剂。 ZPI具有受限的蛋白酶特异性,能够抑制Xa(FXa)和XIa(FXIa)因子,但与其他凝血蛋白酶没有反应性。与ZPI不同,AT是所有凝血蛋白酶的一般抑制剂,也是唯一的因子IXa(FIXa)生理抑制剂。为了了解两个丝氨酸蛋白酶抑制剂的蛋白酶特异性的分子决定因素,我们设计了两个ZPI突变体,其中ZPI反应性中心环的P12-P3'残基被AT的P12-P3'或P12-P7'残基取代( ZPI-AT〜(P12-P3')和ZPI-AT〜(P12-P7'))。在没有PZ的情况下,嵌合体与FXa的反应性提高了约4-25倍。两种嵌合体均抑制FIXa,其速率常数比蛋白酶对AT的抑制率高约2个数量级。 PZ将嵌合体与FIXa的反应性提高了2个数量级,使嵌合体成为FIXa的有效抑制剂,因此ZPI-AT嵌合体对FIXa的PZ介导的抑制活性比磺达肝素的高约20倍。 AT对FIXa的催化抑制作用。进一步的研究表明,ZPI的P1-Tyr被Arg取代足以将丝氨酸蛋白酶抑制剂转变为FIXa的有效抑制剂。 Serpin嵌合体作为FIXa特异抑制剂的潜在治疗作用因发现嵌合体充当其他凝血蛋白酶的有效底物而减弱。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号